Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 29   

Articles published

GSK 1,550.34 -8.16 (-0.52%)
price chart
GlaxoSmithKline settles healthcare fraud case for $3 billion
A GlaxoSmithKline logo is seen outside one of its buildings in west London in this February 6, 2008 file photograph. GlaxoSmithKline Plc has agreed to plead guilty to criminal charges and pay $3 billion to settle the largest case of healthcare fraud in ...
GlaxoSmithKline to pay $3billion fine after pleading guilty to healthcare ...  Daily Mail
GlaxoSmithKline to pay $3B in healthcare fraud  Emirates 24/7
Glaxo in $3 Billion Settlement
Drug maker GlaxoSmithKline PLC agreed to plead guilty to criminal charges of illegally marketing drugs and withholding safety data from U.S.
GlaxoSmithKline to pay $3 billion in fines, the largest health care fraud ...  New York Daily News
Hikma Beats GSK, Pfizer In Argatroban IP Infringement Row
Law360, New York (July 31, 2012, 7:17 PM EDT) -- GlaxoSmithKline PLC and Pfizer Inc. on Tuesday failed to stop Hikma Pharmaceutical Co.
3 UK Stocks With US-Style Dividends And No Tax Withholding For A Dividend ...
... British multinationals in three diverse sectors that pay American-style quarterly dividends that remain stable with consistent growth from year to year: Royal Dutch Shell PLC Class B (RDS.
GSK clinches deal to buy Human Genome for $3 billion
LONDON/BOSTON GlaxoSmithKline Plc is to acquire its long-time partner Human Genome Sciences Inc for a sweetened offer of about $3 billion, ending on friendly terms a three-month hostile pursuit of the U.S.
GlaxoSmithKline to acquire Human Genome Sciences
After spurning a hostile takeover bid from GlaxoSmithKline PLC in April, Human Genome Sciences Inc. said Monday it agreed to be bought by the biopharmaceutical giant for a more lucrative offer valued at $3.6 billion.
HGS Agrees to $3.6B GSK Buyout; Deal Inked at $14.25 Per Share  BioWorld Online
Glaxo Tries to Shake Marketing Questions on Advair
GlaxoSmithKline PLC's $3 billion criminal and civil settlement with the U.S. government this week raises questions about the future of asthma treatment Advair—the company's biggest moneymaker and one of the top-selling drugs in the world.
Big Pharma is in big trouble – or at least it should be
Landmark: GlaxoSmithKline Plc has agreed to plead guilty to criminal charges and pay $3billion to settle the largest case of healthcare fraud in U.S.
Mark Luschini: European Stocks Are A Generational Buying Opportunity (VGK, EWG)
“If you look at Euro-related equities, in terms of their valuation, over the top of U.S. valuations, that disparity is at a 40-year low,” says Mark Luschini, chief investment strategist at Janney Montgomery.
Earnings Preview: Eli Lilly & Co
On July 16, 2012, Reuters reported that Glaxosmithkline Plc is expected to announce an agreement to acquire Human Genome Sciences Inc for about $2.8 billion as soon as Monday, ending three months of its hostile pursuit of the U.S.